ClinicalTrials.gg
CompletedNCT04081363Updated Jan 13, 2023Results posted

Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)

A Phase 2 interventional study of Centanafadine in Attention Deficit Hyperactivity Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 9 Years to 12 Years. Per ClinicalTrials.gov, last updated 2023-01-13.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
9 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity — 5 open to participants now, 5 under way, 5 of them phase 3. centanafadine · Attention Deficit Disorder with Hyperactivity.

Enrollment
20th of 20
13 · median 180
Started
2019
with 3 others
Phase 2
Only one
of the 20
Registered
6th of 20
by date
Lead sponsor
16 of 20
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity, this one is the 20th largest by enrollment, is one of 4 that started in 2019, is the only one in phase 2, and was the 6th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

5 of the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About centanafadine

centanafadine: first FDA approval 2026 (SIMTRIYO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 9 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

With the pharmacokinetics (PK) of centanafadine currently being evaluated in adults. The PK of extended-release centanafadine may differ in children compared to adults due to physiological differences in the gastrointestinal tract. The information in this trial will support pediatric dose selection in future trials.

03

Conditions studied

  • Attention Deficit Hyperactivity Disorder

Keywords

  • ADHD
04

Who can participate

Ages eligible
9 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained from a legally acceptable representative and assent obtained from the participant prior to the initiation of any trial-related procedures.
  • Male or female participants 9 to 12 years of age, inclusive, at the time of informed consent.
  • Participants with documented history of ADHD and confirmation of an ADHD prescription medication.
  • Participant is judged by the investigator to be clinically stable and has not had any psychiatric hospitalizations within the past 12 weeks.

Exclusion criteria

Exclusion Criteria:

  • Participants with a history of intellectual disability as determined by at least 1 of the following: intelligence quotient (IQ) \< 70, or clinical evidence, or a social or school history that is suggestive of an intellectual disability.
  • Participants who have any of the following:

    • Significant risk of committing suicide based on history
    • Current suicidal behavior
    • Imminent risk of injury to self
    • Active suicidal ideation
    • Any lifetime history of suicidal behavior detected by the "Baseline/Screening" version of the Columbia-Suicide Severity Rating Scale (C-SSRS).
  • Participants with a lifetime history of a substance use disorder (as determined by , 5th Edition [DSM-5] criteria), or current substance misuse including alcohol and benzodiazepines, but excluding caffeine and nicotine.
  • Participants with hypothyroidism or hyperthyroidism or an abnormal result for free thyroxine (T4) at screening.
  • Participants who currently have neurological, dermatological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, or gastrointestinal disorders.
  • Participants with insulin-dependent diabetes mellitus.
  • Participants with epilepsy or a history of seizures or a history of severe head trauma or cerebrovascular disease.
  • Any major surgery within 30 days prior to dosing with the medicinal product (IMP).
  • Any history of significant bleeding or hemorrhagic tendencies.
  • Blood transfusion within 30 days prior to dosing with IMP.
  • Participants with a positive drug screen for cocaine, marijuana (even if by prescription), or other illicit drugs, or alcohol, are excluded and may not be retested or rescreened.
  • Participants who have a supine or standing diastolic blood pressure, after resting for at least 5 minutes ≥ 95 mmHg.
  • Participants who participated in a clinical trial and were exposed to IMP within the last 30 days prior to screening or who participated in more than 2 interventional clinical trials within the past year.
  • Participants with a history of true allergic response to a medication or a history of dermatologic adverse reactions or anaphylaxis secondary to drug exposure.
  • Participants who do not tolerate venipuncture or have poor venous access that would cause difficulty when collecting blood samples.
  • Relatives of the trial site employees cannot participate in the trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Swallowed Capsules Cohort

    Participants swallowed two capsules of centanafadine (one containing a 50-milligram \[mg\] dose as extended release beads and other containing a 5-mg dose as immediate-release \[IR\] beads), total dose of 55 mg, orally in the morning of Day 1 following a minimum 8-hour fast.

    Drug: Centanafadine

  • Experimental
    Sprinkled Onto Applesauce Cohort

    Participants were administered centanafadine 55 mg, contents of 2 capsules (one containing a 50-mg dose as beads and other containing a 5-mg dose as IR beads) sprinkled on a tablespoon of applesauce, orally in the morning of Day 1 following a minimum 8-hour fast.

    Drug: Centanafadine

Interventions

  • Extended-release and immediate-release capsules.

    Also known as: EB-1020

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax) of Centanafadine

    Time frame: 1, 2, 3, 4, 6, 8, 10,12 hours post dose on Day 1 and 22-26 hours post dose on Day 2

  2. PK Parameter: Time to Maximum Plasma Concentration (Tmax) of Centanafadine

    Time frame: 1, 2, 3, 4, 6, 8, 10,12 hours post dose on Day 1 and 22-26 hours post dose on Day 2

  3. PK Parameter: Area Under Concentration-time Curve From Time 0 to 12 Hours Postdose (AUC0-12h) of Centanafadine

    Time frame: 0 to 12 hours post dose on Day 1

07

Results

Posted Jan 13, 2023

Participant flow

Participants took part in the study at 2 investigative sites in the United States from 07 October 2019 to 21 December 2019.

Participant flow — Overall Study
MilestoneSwallowed Capsules CohortSprinkled Onto Applesauce Cohort
Started76
Completed66
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryPharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax) of Centanafadine
Time frame:
1, 2, 3, 4, 6, 8, 10,12 hours post dose on Day 1 and 22-26 hours post dose on Day 2
Reported as:
Mean · nanograms per milliliter (ng/mL)
Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax) of Centanafadine
nanograms per milliliter (ng/mL)Swallowed Capsules CohortSprinkled Onto Applesauce Cohort
Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax) of Centanafadine153 ± 51.4129 ± 52.8
PrimaryPK Parameter: Time to Maximum Plasma Concentration (Tmax) of Centanafadine
Time frame:
1, 2, 3, 4, 6, 8, 10,12 hours post dose on Day 1 and 22-26 hours post dose on Day 2
Reported as:
Median · hours (h)
PK Parameter: Time to Maximum Plasma Concentration (Tmax) of Centanafadine
hours (h)Swallowed Capsules CohortSprinkled Onto Applesauce Cohort
PK Parameter: Time to Maximum Plasma Concentration (Tmax) of Centanafadine3.03 (2.00 to 10.00)2.58 (1.03 to 6.00)
PrimaryPK Parameter: Area Under Concentration-time Curve From Time 0 to 12 Hours Postdose (AUC0-12h) of Centanafadine
Time frame:
0 to 12 hours post dose on Day 1
Reported as:
Mean · h*ng/mL
PK Parameter: Area Under Concentration-time Curve From Time 0 to 12 Hours Postdose (AUC0-12h) of Centanafadine
h*ng/mLSwallowed Capsules CohortSprinkled Onto Applesauce Cohort
PK Parameter: Area Under Concentration-time Curve From Time 0 to 12 Hours Postdose (AUC0-12h) of Centanafadine962 ± 320828 ± 346

Adverse events

Collected over Screening up to last follow-up (approximately 30 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Swallowed Capsules Cohort0/7 (0%)0/7 (0%)1/7 (14.3%)
Sprinkled Onto Applesauce Cohort0/6 (0%)0/6 (0%)0/6 (0%)
Most frequent other events
Most frequent other events
EventSwallowed Capsules CohortSprinkled Onto Applesauce Cohort
Vessel Puncture Site BruiseGeneral disorders1/70/6

Baseline characteristics

Enrolled analysis set included all participants who had eligibility to enroll in the trial based on screening process.

Age, Continuous
Age, Continuous(years)Swallowed Capsules CohortSprinkled Onto Applesauce CohortTotal
Mean10.6 ± 1.010.5 ± 1.410.5 ± 1.1
Sex: Female, Male
Sex: Female, Male(Participants)Swallowed Capsules CohortSprinkled Onto Applesauce CohortTotal
Female044
Male729
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Swallowed Capsules CohortSprinkled Onto Applesauce CohortTotal
Hispanic or Latino123
Not Hispanic or Latino6410
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Swallowed Capsules CohortSprinkled Onto Applesauce CohortTotal
American Indian or Alaska Native101
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American022
White6410
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • For additional information regarding sites, contact 844-687-8522
    New York, New York 14618, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Dec 2019, 2 months.

Results were first posted in Jan 2023, 3 years after primary completion. A results delay was requested in Nov 2020.

Of 24 industry-sponsored phase 2 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 2 months is below that.

Counting every sponsor, half of 40 studies reached it within 15 months; a quarter within 5 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2019
First posted
Sep 9, 2019
StartActual
Oct 7, 2019
Primary completionActual
Dec 21, 2019
CompletionActual
Dec 21, 2019
Results delay requested
Nov 23, 2020
Results first posted
Jan 13, 2023
Last update
Jan 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04081363
Responsible party
Sponsor
First posted
Sep 9, 2019
Start date
Oct 7, 2019
Primary completion
Dec 21, 2019
Completion
Dec 21, 2019
Results posted
Jan 13, 2023
Last update
Jan 13, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Centanafadine

Start the discussion